Epristeride is a steroid 5-alpha-reductase inhibitor developed for the treatment of prostatic hyperplasia and acne. The drug reached phase III clinical trial for hyperplasia in the UK, the US and Japan, however, the current status of the drug is unknown.

Fluticasone is a medium-potency synthetic trifluorinated corticosteroid which is used in some countries to manage nasal symptoms of allergic and non-allergic rhinitis. Fluticasone binds and activates glucocorticoid receptor, resulting in the activation of lipocortin. Lipocortin, in turn, inhibits cytosolic phospholipase A2, which triggers a cascade of reactions involved in the synthesis of inflammatory mediators, such as prostaglandins and leukotrienes. Both the furoate and propanoate esters, fluticasone furoate and fluticasone propionate, are much more commonly used as topical anti-inflammatories and inhaled corticosteroids.

EPIMESTROL is a synthetic steroid with estrogenic activity. It was used for the treatment of chronic anovulation and corpus luteum deficiency.

Tralonide, a new topical steroid, can be used in atopic dermatitis.

Quinbolone is an anabolic steroid, developed by Parke-Davis, which was previously marketed in Italy. Quinbolone is a cyclopentenyl ether derivative of Boldenone (B675100) which is also its active metabolite. Quinbolone shows weak androgenic activity. Quinbolone didn`t have liver toxicity.

Trengestone is a steroid substance, a retroprogesterone. It has a strong progestogenic action and stimulating effect on the hypotalamo-hypophyseal system. It does not possess a direct oestrogenic or androgenic action. It indirectly stimulates the oestrogen productivity in the ovary via the central nervous system. The mechanism of action for induction of ovulation is not clear. It is indicated for the treatment of normooestrogenic anovulation. Ovulation occurs after trengestone administration either immediately ater termination of treatment or much later. Another indication for its administration are other functional disorders of the cycle and treatment of imminent abortion. Side-effects are: mastalgia, headache and fatigue.

Nomegestrol acetate (NOMAC) is a 19-norprogesterone derivative with high biological activity at the progesterone receptor, a weak anti-androgenic effect, but with no binding to estrogen, glucocorticoid or mineralocorticoid receptors. Nomegestrol has been developed by the Monaco-based company Théramex SAM (a Teva subsidiary). Nomegestrol acetate has been used successfully for the treatment of some gynaecological disorders (menstrual disturbances, dysmenorrhoea, premenstrual syndrome) and as a component of hormone replacement therapy in combination with estradiol for the relief of menopausal symptoms; it has been approved in Europe as monotherapy for the treatment of the menopausal syndrome, uterine diseases and menorrhagia, and in combination with an estrogen for the treatment of menopausal symptoms. Nomegestrol acetate in combination with estradiol is used as an oral contraceptive.

Cioteronel [CPC 10997, Cyoctol®, X-Andron] is an antiandrogen agent which was in phase II trials for androgenetic alopecia (male pattern baldness), and acne. It was also under development for the oral treatment of benign prostatic hyperplasia, but it was discontinued due to poor efficacy. CPC 10997 was found to be effective in vitro as an antiandrogen without effects on either the estrogen or the progesterone receptors in carcinomas of the breast, ovary and prostate as well as in malignant melanomas. CPC 10997 was found to be more effective against carcinomas of the breast, the kidney, the ovary and the prostate than conventional antineoplastic agents in the majority of tumors tested. The antineoplastic action of CPC 10997 appears to be the inhibition of RNA synthesis, but it has no detectable untoward effects on nonneoplastic cells, in vitro. Although it blocks competitively the binding of dihydrotestosterone (DHT) to its protein receptor, it has no significant effects on either estrogen or progesterone receptors. In view of the very favorable toxicology profiles and in vitro efficacy, further trials using CPC 10997 as an antineoplastic agent are indicated.

Zanoterone (or Win 49596), a steroidal androgen receptor antagonist was studied for the treatment of benign prostatic hyperplasia. The drug did not demonstrate a favorable risk-to-benefit profile and further development was stopped.

Paramethasone is a glucocorticoid. It exerts anti-inflammatory and immunosuppressant actions. Paramethasone stimulates the synthesis of enzymes needed to decrease anti-inflammatory response. It suppresses the immune system by reducing activity and volume of the lymphatic system, thus producing lymphocytopenia decreasing passage of immune complexes and possibly by depressing reactivity of tissue to antigen-antibody interactions.